RT Journal Article
SR Electronic
T1 Sex-specific versus overall cut points for a high sensitivity troponin I assay in predicting 1-year outcomes in emergency patients presenting with chest pain
JF Heart
JO Heart
FD BMJ Publishing Group Ltd and British Cardiovascular Society
SP 120
OP 126
DO 10.1136/heartjnl-2015-308506
VO 102
IS 2
A1 Louise Cullen
A1 Jaimi H Greenslade
A1 Edward W Carlton
A1 Martin Than
A1 John W Pickering
A1 Ariel Ho
A1 Kim Greaves
A1 Sara L Berndt
A1 Richard Body
A1 Kimberley Ryan
A1 William A Parsonage
YR 2016
UL http://heart.bmj.com/content/102/2/120.abstract
AB Objective To evaluate the incidence of major adverse cardiac events (MACE) at 1 year in emergency department (ED) patients with possible acute coronary syndromes, stratified by high sensitivity troponin (hs-cTnI) concentrations using sex-specific cut points compared with overall cut points.Methods In a multicentre observational study of 2841 patients, presentation hs-cTnI concentrations were categorised using sex-specific (women 16 ng/L; men 34 ng/L) and overall (26 ng/L) cut points. The primary outcome was MACE occurring within 1 year of presentation. Patients with hs-cTnI values concentrations within these categories were reported by sex and 1-year MACE. Net reclassification improvement (NRI) was computed to measure the change in prediction after altering the hs-cTnI cut points, and was calculated separately for events and non-events.Results Application of sex-specific 99th percentile cut points rather than the overall cut point of 26 ng/L, reclassified 25 females from having a non-elevated troponin to having an elevated troponin, and 29 males from having an elevated troponin value to having a non-elevated troponin value on presentation. Of these, 7 (28.0%) females and 12 (41.4%) males had a 1-year MACE. There was no reclassification improvement for those with or without 1-year MACE (NRIevents=−1.5%, 95% CI −4.0% to 1.1%; NRInon-events −0.04%, 95% CI −0.5% to 0.4%).Conclusions Sex-specific cut points improve the identification of women but not men at risk for 1-year MACE. The net-effect across the whole ED population with possible cardiac chest pain is minimal. Lowering the clinical cut point for both sexes may be appropriate for prognostic purposes.Trial registration number ISRCTN No. 21109279, ACTRN12609000283279.